DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category GERN
Geron Corp
Geron ( $GERN ) after FY2025 earnings: RYTELO growth is real, but 2026 now becomes an execution year
Geron’s latest earnings did not kill the bullish case and did not fully validate it either. What they did was more useful: they forced the story into a more serious phase, where commercial consistency, spending discipline and the coming IMpactMF readout matter more than launch excitement.
Geron Corp ( $GERN ) Good Year, Tough Quarter Feb 2026
The first full commercial year of RYTELO brought ~$184M in revenue and a growing base of prescribing centers, but a softer Q4 versus expectations and unchanged 2026 guidance triggered a sharp pullback in the stock. Here is what actually happened, why the market reacted this way, and how it fits into the long-term thesis we’ve been following on Merlintrader.
Geron Corp ($GERN) Feb 18 Update
Almost one month after our long-form report at around $1.30, Geron is trading near $1.80. A slow but steady grind higher, driven more by positioning and expectations than by new hard data – with the first catalyst window now approaching: Q4 earnings and the first full-year RYTELO outlook under the new CEO.
GERN Geron Corp
Geron enters 2026 as a newly minted commercial hematology company with one marketed product, RYTELO (imetelstat), and a late-stage program that could pivot the story from niche LR-MDS anemia to broader myelofibrosis survival if the Phase 3 IMpactMF study delivers.
GERN Geron Corp
After decades of telomerase debates and more than one boom-and-bust cycle, Geron finally has an FDA-approved product on the market. Rytelo is generating real revenue, IMpactMF is fully enrolled, and a very loyal retail base is watching every quarterly print and every slide deck, trying to understand whether this is the beginning of a long compounding story or just the payoff of a very long wait.